Analysts Say Buy These Stocks: Yahoo! Inc. (NASDAQ:YHOO), Carmike Cinemas, Inc. (NASDAQ:CKEC), Fidus Investment Corporation (NASDAQ:FDUS), Nivalis Therapeutics Inc (NASDAQ:NVLS)

Wall Street analysts are maintaining Buy rating on Yahoo! Inc. (NASDAQ:YHOO) company shares.  The one year target on the name currently stands at $37.8800.  The stock recently touched $37.0699 and has moved in the range of $36.5400 - 37.5000 during the current session.  Based on a recent bid this places the stock +41.7587% away from the 52-week floor of $26.1500 and -19.7100% away from the 52-week ceiling of $46.1700.

When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary.  Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth.  Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year.  Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.

Carmike Cinemas, Inc. (NASDAQ:CKEC) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $30.87 on the stock. The stock is currently trading +27.42% away from its 200-day moving average of $23.52. Based on a recent trade, shares of Carmike Cinemas, Inc. are -11.20% away from the 52-week high of $33.75 and +61.83% away from the 52-week low of $18.52.

Analysts are estimating that the company will report earnings of $0.66 for the current year and $0.35 for next quarter. The stock closed the most recent trading session at $30.01.

Shares of Fidus Investment Corporation (NASDAQ:FDUS) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $16.900 price target and Buy rating according to the covering analysts.  During today’s session the stock hit $15.392 or -0.889% from the previous close, while moving in the range of $15.392 - 15.790.

Shares of Nivalis Therapeutics Inc (NASDAQ:NVLS) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $25.00 price target according to the covering analysts.  During today’s session the stock hit $4.35 or -0.23% from the previous close, while moving in the range of $4.27 - 4.53.  This puts the stock -78.76% away from the 52-week high of $20.43 and +17.93% away from the 52-week low of $3.68.

Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm.  The consensus rating simply provides an average of those recommendations.  It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Add Comment